Dextrostat

Narcolepsy, Attention Deficit Hyperactivity Disorder

Treatment

2 FDA approvals

20 Active Studies for Dextrostat

What is Dextrostat

Dextroamphetamine

The Generic name of this drug

Treatment Summary

Dextroamphetamine is a medication approved by the FDA in 2001 to treat attention deficit hyperactivity disorder (ADHD). It is an enantiomer of amphetamine and works by stimulating the nervous system.

Dextrostat

is the brand name

image of different drug pills on a surface

Dextrostat Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Dextrostat

Dextroamphetamine

1975

569

Approved as Treatment by the FDA

Dextroamphetamine, also known as Dextrostat, is approved by the FDA for 2 uses such as Narcolepsy and Attention Deficit Hyperactivity Disorder .

Narcolepsy

Helps manage Narcolepsy

Attention Deficit Hyperactivity Disorder

Used to treat Attention Deficit Hyperactivity Disorder (ADHD) in combination with Amphetamine

Effectiveness

How Dextrostat Affects Patients

Dextroamphetamine is a substance that affects the Central Nervous System to produce stimulating effects. It increases blood pressure, helps open breathing passages, and stimulates breathing. The exact way it works is not known.

How Dextrostat works in the body

Amphetamines work by stopping the reabsorption of dopamine in the brain. They also increase the amount of dopamine released and stimulate it to move in reverse. In some cases, amphetamines may also change the number of dopamine transporters in the brain.

When to interrupt dosage

The measure of Dextrostat is contingent upon the diagnosed condition. The amount of dosage is also contingent upon the delivery method (e.g. Tablet or Oral) referenced in the table below.

Condition

Dosage

Administration

Narcolepsy

, 5.0 mg, 10.0 mg, 15.0 mg, 5.0 mg/mL, 2.5 mg, 7.5 mg, 20.0 mg, 30.0 mg, 3.125 mg, 6.25 mg, 9.375 mg, 12.5 mg, 1.875 mg, 1.25 mg, 3.75 mg, 25.0 mg, 18.75 mg, 60.0 mg, 40.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Liquid - Oral, Liquid, Tablet, Tablet - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral

Attention Deficit Hyperactivity Disorder

, 5.0 mg, 10.0 mg, 15.0 mg, 5.0 mg/mL, 2.5 mg, 7.5 mg, 20.0 mg, 30.0 mg, 3.125 mg, 6.25 mg, 9.375 mg, 12.5 mg, 1.875 mg, 1.25 mg, 3.75 mg, 25.0 mg, 18.75 mg, 60.0 mg, 40.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Liquid - Oral, Liquid, Tablet, Tablet - Oral, Solution, Solution - Oral, Capsule, Capsule - Oral

Warnings

Dextrostat has nine contraindications and should not be ingested if experiencing any of the circumstances in the following table.

Dextrostat Contraindications

Condition

Risk Level

Notes

Hypertensive disease

Do Not Combine

Drug abuse

Do Not Combine

Pulse Frequency

Do Not Combine

Open-angle glaucoma

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

advanced arteriosclerosis

Do Not Combine

Hyperthyroidism

Do Not Combine

Agitation

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Dextroamphetamine may interact with Pulse Frequency

There are 20 known major drug interactions with Dextrostat.

Common Dextrostat Drug Interactions

Drug Name

Risk Level

Description

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Dextroamphetamine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Dextroamphetamine.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Dextroamphetamine.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Dextroamphetamine.

Flecainide

Major

The metabolism of Flecainide can be decreased when combined with Dextroamphetamine.

Dextrostat Toxicity & Overdose Risk

Taking dextroamphetamine during pregnancy could lead to birth defects and other issues in the baby, such as tracheoesophageal fistula, anal atresia, low birthweight, and withdrawal symptoms. Women should not take this drug while breastfeeding as it can be passed to the baby through breast milk. Dextroamphetamine should also not be given to children under 3 years old due to a lack of research on long-term effects.

image of a doctor in a lab doing drug, clinical research

Dextrostat Novel Uses: Which Conditions Have a Clinical Trial Featuring Dextrostat?

84 active studies are currently being conducted to assess the potential of Dextrostat in the management of Narcolepsy.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Dextrostat Reviews: What are patients saying about Dextrostat?

5

Patient Review

7/5/2009

Dextrostat for Overweight

I generally forget to take this drug every few hours, but when I do it really helps me. It's a great medication, but because it is considered a class A narcotic, you're made to feel like a criminal when purchasing it from the store.

5

Patient Review

7/21/2009

Dextrostat for Overweight

This drug not only helps me focus, but it seems to help curb my appetite too.

5

Patient Review

2/13/2008

Dextrostat for Attention Deficit Disorder with Hyperactivity

5

Patient Review

3/6/2010

Dextrostat for Recurring Sleep Episodes During the Day

This is the best of the generic options out there.

5

Patient Review

1/26/2013

Dextrostat for Attention Deficit Disorder with Hyperactivity

The medication was very effective.

4.7

Patient Review

7/29/2009

Dextrostat for Attention Deficit Disorder with Hyperactivity

This medication has really changed my life for the better. I sometimes wonder how different my childhood would have been if they knew more about ADHD back then, but there's no use dwelling on the past. This drug has helped me make up for lost time and I can't recommend it enough.

4.7

Patient Review

9/25/2008

Dextrostat for Attention Deficit Disorder with Hyperactivity

3.3

Patient Review

6/21/2008

Dextrostat for Attention Deficit Disorder with Hyperactivity

2.7

Patient Review

4/1/2009

Dextrostat for Recurring Sleep Episodes During the Day

This medication has made a big difference in my life. I believe ADD/ADHD is under diagnosed in adults that were not diagnosed as children. All my life I have had to live by making myself notes for everything from Dr's appts to what room I was goingto clean the nest day. I donthave to make notes for my life anymore when taking this medication. Thanks, Ambe

2

Patient Review

3/13/2008

Dextrostat for Attention Deficit Disorder with Hyperactivity

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dextrostat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Dextrostat a controlled substance?

"People with a history of drug and alcohol abuse shouldn't take dextroamphetamine because it's a controlled substance with a high risk of abuse, misuse, and dependency. Taking only the amount prescribed by a healthcare provider lowers the risk of abuse and overdose."

Answered by AI

Is Dextrostat still available?

"The Dextrostat brand name has been discontinued in the U.S. Generic versions of this product have been approved by the FDA and may be available."

Answered by AI

Is Dextrostat the same as Adderall?

"The drug Dexedrine is similar to Adderall in that they are both in the amphetamine class of medications. The difference is that Dexedrine only contains dextroamphetamine while Adderall also contains pure amphetamine. As a prescription drug, Dexedrine is available in tablet, liquid, or extended-release capsule form, all of which are taken orally."

Answered by AI

What is Dextrostat used for?

"The medication is used to treat attention deficit hyperactivity disorder by changing the amounts of certain natural substances in the brain. Dextroamphetamine, a stimulant, belongs to a class of drugs known to have this effect."

Answered by AI

Clinical Trials for Dextrostat

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Dextrostat clinical trials?

We made a collection of clinical trials featuring Dextrostat, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Dextrostat clinical trials?

We made a collection of clinical trials featuring Dextrostat, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Dextrostat clinical trials?

We made a collection of clinical trials featuring Dextrostat, we think they might fit your search criteria.
Go to Trials